Community Acquired Respiratory Viruses

  • Marshall PlitEmail author


Community acquired respiratory infections (CARV) are associated with severe acute illness and potentially long term sequelae in lung transplant patients. CARV triggers innate and adaptive immune responses that may amplify lung allograft injury and lead to chronic lung allograft disease.

Paramyxoviridea, the most important of which include respiratory syncytial, parainfluenzae and human metapneumovirus, have a propensity to cause a necrotizing bronchiolitis with an acute severe illness and long-term loss of allograft function; hence the need for specific therapy including corticosteroids and ribavirin. Human rhinovirus can persist and has been associated with bronchiolitis obliterans in lung transplant patients. Influenza has been associated with severe complications and death in immunosuppressed patients. Unfortunately, the efficacy of the influenza vaccine is variable ranging from 16 to 60%.

The rapid and accurate detection of CARV by means of nasopharyngeal swabs for viral PCR has had a major impact on the early diagnosis and management of these infections.


Lung transplant Viruses Chronic lung allograft dysfunction Bronchiolitis obliterans 


  1. 1.
    Burton CM, Carlsen J, Mortensen J, Andersen CB, Milman N, Iversen M. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2007;26:681–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Versluys AB, Rossen JW, van Ewijk B, Schuurman R, Bierings MB, Boelens JJ. Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes. Biol Blood Marrow Transplant. 2010;16:782–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Breese Hall C. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917–28.CrossRefGoogle Scholar
  4. 4.
    Henrickson KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16:242–64.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    van den Hoogen BG, de Jong JC, Groen J. A newly discovered human metapneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7:719–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Greensill J, McNamara PS, Dove W, Flanagan B, Smyth RL, Hart CA. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg Infect Dis. 2003;9(3):372–5.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014;33:127–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011;11:1071–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Gotlieb J. Community-acquired respiratory viruses. Semin Respir Crit Care Med. 2018;2:213–8.Google Scholar
  10. 10.
    Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, Johnson G, Ayers M, Siegal D, Humar A. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5:2031–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Kumar D, Husain S, Chen MH, Moussa G, Himsworth D, Manuel O, Studer S, Pakstis D, McCurry K, Doucette K, Pilewski J, Janeczko R, Humar A. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation. 2010;89:1028–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Winter JB, Gouw AS, Groen M, Wildevuur C, Prop J. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation. 1994;57:418–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Wendt CH, Fox JM, Hertz MI. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant. 1995;14:479–85.PubMedGoogle Scholar
  14. 14.
    Vilchez RA, McCurry K, Dauber J, Iacono A, Keenan R, Zeevi A, Griffith B, Kusne S. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis. 2001;33:2004–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection - myth or reality? Am J Transplant. 2003;3:245–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559–66.CrossRefPubMedGoogle Scholar
  17. 17.
    Hopkins P, McNeil K, Kermeen F, Musk M, McQueen E, Mackay I, Sloots T, Nissen M. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178:876–81.CrossRefPubMedGoogle Scholar
  18. 18.
    Gottlieb J, Schulz TF, Welte T, Fuehner T, Dierich M, Simon AR, Engelmann I. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation. 2009;87:1530–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, Mohanakumar T, Trulock EP, Walter MJ. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170:181–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Uckay I, Gasche-Soccal PM, Kaiser L, Stern R, Mazza-Stalder J, Aubert JD, van Delden C. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy. J Heart Lung Transplant. 2010;29:299–305.CrossRefPubMedGoogle Scholar
  21. 21.
    Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plit ML, Carter IW, Malouf MA. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114–9.CrossRefPubMedGoogle Scholar
  22. 22.
    McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010;12:38–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Pelaez A, Lyon GM, Force SD, Ramirez AM, Neujahr DC, Foster M, Naik PM, Gal AA, Mitchell PO, Lawrence EC. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28:67–71.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Burrows FS, Carlos LM, Benzimra M, Marriott DJ, Havryk AP, Plit ML, Malouf MA, Glanville AR. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency. J Heart Lung Transplant. 2015;34(7):958–62.CrossRefPubMedGoogle Scholar
  26. 26.
    Gottlieb J, Zamora MR, Hodges T, Musk AW, Sommerwerk U, Dilling D, Arcasoy S, DeVincenzo J, Karsten V, Shah S, Bettencourt BR, Cehelsky J, Nochur S, Gollob J, Vaishnaw A, Simon AR, Glanville AR. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35:213–21.CrossRefPubMedGoogle Scholar
  27. 27.
    Jacobs SE, Lamson DM, George KS, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev. 2013;26:135–62.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Murali S, Langston AA, Nolte FS, Banks G, Martin R, Caliendo AM. Detection of respiratory viruses with a multiplex polymerase chain reaction assay (multicode-plx respiratory virus panel) in patients with hematologic malignancies. Leuk Lymphoma. 2009;50:619–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Kraft CS, Jacob JT, Sears MH, Burd EM, Caliendo AM, Lyon GM. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. J Clin Microbiol. 2012;50:1061–3.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kaiser L, Aubert JD, Pache JC, Deffernez C, Rochat T, Garbino J, Wunderli W, Meylan P, Yerly S, Perrin L, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med. 2006;174:1392–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Costa C, Bergallo M, Astegiano S, Sidoti F, Terlizzi ME, Gambarino S, Curtoni A, Simeone S, Solidoro P, Cavallo R. Detection of human rhinoviruses in the lower respiratory tract of lung transplant recipients. Arch Virol. 2011;156:1439–43.CrossRefPubMedGoogle Scholar
  32. 32.
    Sayah DM, Koff JL, Leard LE, Hays SR, Golden JA, Singer JP. Rhinovirus and other respiratory viruses exert different effects on lung allograft function that are not mediated through acute rejection. Clin Transpl. 2013;27:E64–71.CrossRefGoogle Scholar
  33. 33.
    Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation. Transpl Infect Dis. 2001;3:138–48.CrossRefPubMedGoogle Scholar
  34. 34.
    Humar A, Doucette K, Kumar D, Pang XL, Lien D, Jackson K, Preiksaitis J. Assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance. J Heart Lung Transplant. 2006;25:1441–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Demicheli V, Jefferson T, Al-Ansary LA, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2014:CD001269. doi:10.1002/14651858.CD001269.pub5.
  36. 36.
    Nicholson KG, Aoki FY, Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874.CrossRefPubMedGoogle Scholar
  37. 37.
    Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet. 1998;352:1877.Google Scholar
  38. 38.
    Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385:1729.CrossRefPubMedGoogle Scholar
  41. 41.
    Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and prophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Recomm Rep. 2011;60:1.PubMedGoogle Scholar
  42. 42.
    Statement by the Infectious Disease Society of America (IDSA) on the recent publication on “Neuraminidase inhibitors for preventing and treating influenza in health adults and children”. 3 Jan 2015.Google Scholar
  43. 43.
    “Have you heard” CDC recommendations for influenza antiviral medications remain. 3 Jan 2015.Google Scholar
  44. 44.
    Schwarze J, Mackenzie KJ. Novel insights into immune and inflammatory responses to respiratory viruses. Thorax. 2013;68:108–10.CrossRefPubMedGoogle Scholar
  45. 45.
    Kuo E, Bharat A, Shih J, Street T, Norris J, Liu W, Parks W, Walter M, Patterson GA, Mohanakumar T. Role of airway epithelial injury in murine orthotopic tracheal allograft rejection. Ann Thorac Surg. 2006;82:1226–33.CrossRefPubMedGoogle Scholar
  46. 46.
    Rinaldo CR Jr. Modulation of major histocompatibility complex antigen expression by viral infection. Am J Pathol. 1994;144:637–50.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Papi A, Stanciu LA, Papadopoulos NG, Teran LM, Holgate ST, Johnston SL. Rhinovirus infection induces major histocompatibility complex class 1 and costimulatory molecule upregulation on respiratory epithelial cells. J Infect Dis. 2000;181:1780–4.CrossRefPubMedGoogle Scholar
  48. 48.
    Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, Meyer KC, Hayney MS, Braun RK, Greenspan DS, et al. IL-17-dependent cellular immunity to collagen type v predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117:3498–506.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Goers TA, Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. De novo production of k-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol. 2008;180:4487–94.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Halloran PF, Homik J, Goes N, Lui SL, Urmson J, Ramassar V, Cockfield SM. The “injury response”: a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc. 1997;29:79–81.CrossRefPubMedGoogle Scholar
  51. 51.
    Bharat A, Kuo E, Saini D, Steward N, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T. Respiratory virus-induced dysregulation of T-regulatory cells leads to chronic rejection. Ann Thorac Surg. 2010;90:1637–44; discussion 1644.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Sakaguchi S. Naturally arising foxp3-expressing cd25+cd4+ regulatory t cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.CrossRefPubMedGoogle Scholar
  53. 53.
    Zdrenghea MT, Telcian AG, Laza-Stanca V, Bellettato CM, Edwards MR, Nikonova A, Khaitov MR, Azimi N, Groh V, Mallia P, et al. RSV infection modulates IL-15 production and mica levels in respiratory epithelial cells. Eur Respir J. 2012;39:712–20.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Thoracic Medicine and Medical Lung Transplant UnitSt Vincent’s HospitalSydneyAustralia

Personalised recommendations